this result will also entitle the company to large amounts of non dilutive funding in the period ahead for this cardiovascular category. Aptoll recieved 6 million on their infarct results in non dilutive funding
Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.67M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.5¢ | $74.58K | 302.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15657 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 921 | 1 |
View Market Depth
| Last trade - 10.33am 23/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |